money moves

Houston-based battery innovators receive $4M in federal funding

Houston-based Zeta Energy has fresh funding from the government. Image via Zeta Energy

Houston-based Zeta Energy announced this week that it was selected to receive $4 million in federal funding for the development of efficient electric vehicle batteries.

The funds come from the U.S. Department of Energy's ARPA-E Electric Vehicles for American Low-Carbon Living, or EVs4ALL, program, which aims to increase the number of EVs on the roads by boosting the country’s supply chain of affordable, convenient, reliable and safe batteries.

Zeta Energy is one of 12 groups in the U.S. to receive funding from the program, which awarded $42 million in total.

“Electric vehicle sales in America have tripled since the start of this Administration and by addressing battery efficiency, resiliency and affordability, the projects announced today will make EVs attractive to even more drivers,” U.S. Secretary of Energy Jennifer M. Granholm said in a statement released earlier this week. “This is a win-win for our efforts to fight climate change and power America’s clean transportation future with technologies produced by researchers and scientists right here at home.”

Other teams to receive funding include 24M Technologies, national laboratories and universities like The Ohio State University, University of Maryland, Virginia Tech, among others. Zeta is the only Texas-based company to receive funds. It received one of the largest grants among the group.

"We are thrilled to have been selected for funding by the ARPA-E EVs4ALL program," Zeta Energy CEO Tom Pilette said in a statement. "We have been working hard to make this technology a reality, and we are really grateful to receive this recognition of the promise of our technology and the progress we have made on it."

Zeta Energy is known for its lithium sulfur batteries that traditionally have not been long lasting. While sulfur is an economical and abundant material, it traditionally would dissolve after a few uses in lithium sulfur batteries.

However, Zeta uses its proprietary sulfur-based cathodes and lithium metal anodes that have shown to have higher capacity and density and better safety profiles, according to the company's website.

According to ARPAE, the company will create a new anode that will "be highly accessible and rechargeable" with the funding.

Zeta Energy

closed a $23 million series A round led by New York VC firm Moore Strategic Ventures about a year ago. In addition to applications for electric vehicles, the company's technology is also expected to have uses in grid energy storage.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted